1. Douglas Pharmaceuticals Ltd
Graeme Douglas
Managing Director

3. Company history Year Key Event 1967 Trading commences 1972
Frusemide registered
1983
Penicillin plant commissioned (solid oral in ‘85)
1986
Purchase of Karitane product license
1988
Loss of 3 major agencies
1989
First Australian market product registration
1990
Henderson site opened (new plant in 1996)
1996
Sale of Karicare to Nutricia
2002
Isotretinoin first registered in Europe
2006
Sale of Australian subsidiary
2007
FDA Approval
2008
Purchase of nutraceutical business line
2010
Added softgel capacity to manufacturing capabilities

4. Sales Growth
Growth In Revenue – 2011B (NZ$m’s)
CAGR 14%

5. Registration & Licensing
Product Development Process
Ideas
Product Design
Evaluation
Detailed Scoping
Scale-up
Bio-studies
Registration & Licensing
Launch
Company Strategy
Market Assessment
Patent Search
Feasibility
API Source
Formulation
Analytical
Validation
Pilot Scale
Large Scale
Validation
Stability
Regulatory
Costings
Licensing
Stability
Clinical
Stability
                             G7 G6 G5 G4 G3
18-36 Months
NZ$0.5 to 1.5Mn G2 G1
6-12 Months
NZ$0.3 to 1Mn
2-10 Months
NZ$0.5 to 1.5Mn
Months
NZ$0.5 to 2Mn
TOTAL (per Project)
years duration and NZ$ 2.0 to 6.0Mn
3-6 Months
NZ$ 70K

6. Continued Investment in R&D
Douglas Pharmaceuticals Turnover and R&D Spend (2004 – 2011B)
NZ$M’s
NZ$M’s
Annual Turnover
Annual R&D Spend

7. Oratane (Isotretinoin Softgel Capsules)
Isomer of Vitamin A acid
Highly effective treatment for Acne
Product is a challenge to develop, manufacture & register
Douglas developed the first generic
A huge success for Douglas: 40 customers in 26 countries
Oratane has annual sales of over NZ$ 40 million

8. Global Growth Accelerated Product and New Market Growth Are Key Elements of Our 2015 Growth Strategy
Existing markets
New markets
Key Objectives
2010
2015
Number of Douglas Developed Products 23 45
Total Sales Revenues (Domestic and Export)
$139m
$250m

9. Thank You